Drug metabolic stability in early drug discovery to develop potential lead compounds

References

• Acikgöz A, Giri S, Cho M-G, Bader A. 2013. Morphological and functional analysis of hepatocyte spheroids generated on poly-HEMA-treated surfaces under the influence of fetal calf serum and nonparenchymal cells. Biomolecules. 3(1):242–269.
   PubMedGoogle Scholar
• Al-Obeidi F, Castrucci AMdL, Hadley ME, Hruby VJ. 1989. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 32(12):2555–2561.
   PubMed Web of Science ®Google Scholar
• Armishaw CJ, Dutton JL, Craik DJ, Alewood PF. 2009. Establishing regiocontrol of disulfide bond isomers of α‐conotoxin ImI via the synthesis of N‐to‐C cyclic analogs. Pept Sci. 94(3):307–313.
   Web of Science ®Google Scholar
• Bajad SU, Lu W, Kimball EH, Yuan J, Peterson C, Rabinowitz JD. 2006. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J Chromatogr A. 1125(1):76–88.
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Stańczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H. 2006. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep. 58(4):453–472.
   PubMed Web of Science ®Google Scholar
• Bardal SK, Waechter JE, Martin DS. 2011. Chapter 2—Pharmacokinetics. In: Applied Pharmacology, Content Repository Only. US: Elsevier Health; 17–34.
   Google Scholar
• Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. 2007. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 8(1):33–45.
   PubMed Web of Science ®Google Scholar
• Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C, Goldring CE, Park K, Regan SL, Walker T, et al. 2018. Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study. Toxicol Sci. 162(2):655–666.
   PubMed Web of Science ®Google Scholar
• Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, Puigvert LF, Dankers AC, Jacobs F, Snoeys J. 2016. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep. 6(1):1–13.
   PubMed Web of Science ®Google Scholar
• Besser D, MüLler B, Agricola I, Reissmann S. 2000. Synthesis of differentially protected N‐acylated reduced pseudodipeptides as building units for backbone cyclic peptides. J Peptide Sci. 6(3):130–138.
   PubMed Web of Science ®Google Scholar
• Besser D, Müller B, Kleinwächter P, Greiner G, Seyfarth L, Steinmetzer T, Arad O, Reissmann S. 2000. Synthesis and characterization of octapeptide somatostatin analogues with backbone cyclization: comparison of different strategies, biological activities and enzymatic stabilities. J Prakt Chem. 342(6):537–545.
   Google Scholar
• Bigeleisen J, Wolfsberg M, Prigogine I. 1958. Theoretical and experimental aspects of isotope effects in chemical kinetics. A Adv. Chem. Phys. 1:15–76.
   Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 31(7):815–832.
   PubMed Web of Science ®Google Scholar
• Blanchard SG, Andrews RC, Brown PJ, Gan L-SL, Lee FW, Sinhababu AK, Wheeler TN. 2002. Discovery of bioavailable inhibitors of secretory phospholipase A 2. In: Integration of Pharmaceutical Discovery and Development. Springer; p. 445–463.
   Google Scholar
• Brian Houston J, Carlile DJ. 1997. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev. 29(4):891–922.
   PubMed Web of Science ®Google Scholar
• Brightman FA, Leahy DE, Searle GE, Thomas S. 2006. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab Dispos. 34(1):84–93.
   PubMed Web of Science ®Google Scholar
• Cargnin S, Serafini M, Pirali T. 2019. A primer of deuterium in drug design. Future Med Chem. 11(16):2039–2042.
   PubMed Web of Science ®Google Scholar
• Carlile DJ, Hakooz N, Bayliss MK, Houston JB. 1999. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol. 47(6):625–635.
   PubMed Web of Science ®Google Scholar
• Charpentier B, Dor A, Roy P, England P, Pham H, Durieux C, Roques BP. 1989. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 32(6):1184–1190.
   PubMed Web of Science ®Google Scholar
• Chen AA, Thomas DK, Ong LL, Schwartz RE, Golub TR, Bhatia SN. 2011. Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci USA. 108(29):11842–11847.
   PubMed Web of Science ®Google Scholar
• Cheneval O, Schroeder CI, Durek T, Walsh P, Huang Y-H, Liras S, Price DA, Craik DJ. 2014. Fmoc-based synthesis of disulfide-rich cyclic peptides. J Org Chem. 79(12):5538–5544.
   PubMed Web of Science ®Google Scholar
• Chiba M, Ishii Y, Sugiyama Y. 2009. Prediction of hepatic clearance in human from in vitro data for successful drug development. Aaps J. 11(2):262–276.
   PubMed Web of Science ®Google Scholar
• Chiou WL. 1982. The physiological significance of total body clearance in pharmacokinetic studies. J Clin Hosp Pharm. 7(1):25–30.
   PubMedGoogle Scholar
• Clark RJ, Fischer H, Dempster L, Daly NL, Rosengren KJ, Nevin ST, Meunier FA, Adams DJ, Craik DJ. 2005. Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. Proc Natl Acad Sci USA. 102(39):13767–13772.
   PubMed Web of Science ®Google Scholar
• Clark RJ, Jensen J, Nevin ST, Callaghan BP, Adams DJ, Craik DJ. 2010. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew Chem Int Ed Engl. 49(37):6545–6548.
   PubMed Web of Science ®Google Scholar
• Dean M, Sung VW. 2018. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug Des Devel Ther. 12:313–319.
   PubMed Web of Science ®Google Scholar
• Dowd F. 2017. Pharmacokinetics: the absorption, distribution, and fate of drugs. In: Pharmacology and therapeutics for dentistry. 7th ed. St Louis (MO): Mosby, Inc.; p. 15–43.
   Google Scholar
• Eddershaw PJ, Dickins M. 1999. Advances in in vitro drug metabolism screening. J Pharm Sci Technol. 2(1):13–19.
   Google Scholar
• Ellson R, Mutz M, Browning B, Lee L Jr Miller MF Jr, Papen JR. 2003. Transfer of low nanoliter volumes between microplates using focused acoustics—automation considerations. J Lab Autom. 8(5):29–34.
   Google Scholar
• Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. 2000. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos. 28(5):560–566.
   PubMed Web of Science ®Google Scholar
• Frey AJ, Feldman DR, Trefely S, Worth AJ, Basu SS, Snyder NW. 2016. LC-quadrupole/Orbitrap high-resolution mass spectrometry enables stable isotope-resolved simultaneous quantification and ¹³C-isotopic labeling of acyl-coenzyme a thioesters. Anal Bioanal Chem. 408(13):3651–3658.
   PubMed Web of Science ®Google Scholar
• Gant TG. 2014. Using deuterium in drug discovery: leaving the label in the drug. J Med Chem. 57(9):3595–3611.
   PubMed Web of Science ®Google Scholar
• Gilon C, Halle D, Chorev M, Selinger Z, Byk G. 1991. Backbone cyclization: a new method for conferring conformational constraint on peptides. Biopolymers. 31(6):745–750.
   PubMed Web of Science ®Google Scholar
• Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, et al. 2013. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 87(8):1315–1530.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon M, Donato M, Castell J, Jover R. 2003. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab. 4(4):292–312.
   PubMed Web of Science ®Google Scholar
• Gu L, Jones AD, Last RL. 2007. LC-MS/MS assay for protein amino acids and metabolically related compounds for large-scale screening of metabolic phenotypes. Anal Chem. 79(21):8067–8075.
   PubMed Web of Science ®Google Scholar
• Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB. 2006. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res. 23(3):533–539.
   PubMed Web of Science ®Google Scholar
• Halai R, Callaghan B, Daly NL, Clark RJ, Adams DJ, Craik DJ. 2011. Effects of cyclization on stability, structure, and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABAB receptor. J Med Chem. 54(19):6984–6992.
   PubMed Web of Science ®Google Scholar
• Harbeson SL, Morgan AJ, Liu JF, Aslanian AM, Nguyen S, Bridson GW, Brummel CL, Wu L, Tung RD, Pilja L. 2017. Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther. 362(2):359–367.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. 1992. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 52(5):453–457.
   PubMed Web of Science ®Google Scholar
• Hemu X, Taichi M, Qiu Y, Liu DX, Tam JP. 2013. Biomimetic synthesis of cyclic peptides using novel thioester surrogates. Pept. Sci. 100(5):492–501.
   Web of Science ®Google Scholar
• Hoener BA. 1994. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm Drug Dispos. 15(4):295–304.
   PubMed Web of Science ®Google Scholar
• Hollenbeck T, Thibodeaux S, White P, Westling L, Chong A, Isbell J. 2020. Acoustic droplet ejection and open port interface for rapid analysis of metabolic stability assays. J Pharm Sci. 109(11):3285–3291.
   PubMed Web of Science ®Google Scholar
• Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 47(9):1469–1479.
   PubMed Web of Science ®Google Scholar
• Humphrey M, Smith D. 1992. Role of metabolism and pharmacokinetic studies in the discovery of new drugs-present and future perspectives. Xenobiotica. 22(7):743–755.
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. 2004. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res. 21(5):785–792.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. 1997. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther. 73(2):147–171.
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Bai AA, Kulkarni AF, Moghaddam M. 2016. Efficiency in drug discovery: liver S9 fraction assay as a screen for metabolic stability. Drug Metab Lett. 10(2):83–90.
   PubMedGoogle Scholar
• Jia L, Linnik MD, Jack RM, Yu L. 2001. Biostability and pharmacokinetics of LJP 920, an octameric Gal (alpha1-3) Gal conjugate for the inhibition of xenotransplantation rejection. J Pharm Pharmacol. 53(7):999–1005.
   PubMed Web of Science ®Google Scholar
• Jia L, Liu X. 2007. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab. 8(8):822–829.
   PubMed Web of Science ®Google Scholar
• Jia L, Wong H, Wang Y, Garza M, Weitman SD. 2003. Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J Pharm Sci. 92(1):161–172.
   PubMed Web of Science ®Google Scholar
• Jiang J, Pang X, Li L, Dai X, Diao X, Chen X, Zhong D, Wang Y, Chen Y. 2016. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide. Drug Des Devel Ther. 10:2181–2191.
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Janefeldt A, Vilén L, Vildhede A, Samuelsson K, Milton L, Björkbom A, Persson M, Leandersson C, Andersson TB, et al. 2021. Primary human hepatocyte spheroid model as a 3D in vitro platform for metabolism studies. J. Pharm. Sci. 110(1):422–431.
   PubMed Web of Science ®Google Scholar
• Kassahun K, Fandozzi C, Gauthier DR, Jr, Shipley LA. 2012. Cathepsin cysteine protease inhibitors. Google Patents.
   Google Scholar
• Katsnelson A. 2013. Heavy drugs draw heavy interest from pharma backers. Nat Med. 19(6):656.
   PubMed Web of Science ®Google Scholar
• Kaufmann A, Butcher P, Maden K, Walker S, Widmer M. 2010. Comprehensive comparison of liquid chromatography selectivity as provided by two types of liquid chromatography detectors (high resolution mass spectrometry and tandem mass spectrometry): "where is the crossover point?"). Anal Chim Acta. 673(1):60–72.
   PubMed Web of Science ®Google Scholar
• Kuchitsu K, Bartell L. 1962. Effect of anharmonic vibrations on the bond lengths of polyatomic molecules. I. Model of force field and application to water. Chem Phys. 36(9):2460–2469.
   Web of Science ®Google Scholar
• Kumar GN, Surapaneni S. 2001. Role of drug metabolism in drug discovery and development. Med Res Rev. 21(5):397–411.
   PubMed Web of Science ®Google Scholar
• Larkin AL, Rodrigues RR, Murali T, Rajagopalan P. 2013. Designing a multicellular organotypic 3D liver model with a detachable, nanoscale polymeric space of disse. Tissue Eng Part C Methods. 19(11):875–884.
   PubMed Web of Science ®Google Scholar
• Lau YY, Sapidou E, Cui X, White RE, Cheng K-C. 2002. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos. 30(12):1446–1454.
   PubMed Web of Science ®Google Scholar
• Li CY, Stevens KR, Schwartz RE, Alejandro BS, Huang JH, Bhatia SN. 2014. Micropatterned cell-cell interactions enable functional encapsulation of primary hepatocytes in hydrogel microtissues. Tissue Eng Part A. 20(15–16):2200–2212.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang J, Wang Y, Hu F, Zhang Y. 2019. Metabolism of vesatolimod in rat, dog, and human liver microsomes: metabolic stability assessment, metabolite identification, and interspecies comparison. Drug Test Anal. 11(2):240–249.
   PubMed Web of Science ®Google Scholar
• Li Z, Xu X, Li G, Fu X, Liu Y, Feng Y, Wang M, Ouyang Y, Han J. 2017. Improving metabolic stability with deuterium: the discovery of GPU-028, a potent free fatty acid receptor 4 agonists. Bioorg Med Chem. 25(24):6647–6652.
   PubMed Web of Science ®Google Scholar
• Linde Y, Ovadia O, Safrai E, Xiang Z, Portillo FP, Shalev DE, Haskell‐Luevano C, Hoffman A, Gilon C. 2008. Structure‐activity relationship and metabolic stability studies of backbone cyclization and N‐methylation of melanocortin peptides. Pept Sci. 90(5):671–682.
   Web of Science ®Google Scholar
• Lovelace ES, Armishaw CJ, Colgrave ML, Wahlstrom ME, Alewood PF, Daly NL, Craik DJ. 2006. Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter. J Med Chem. 49(22):6561–6568.
   PubMed Web of Science ®Google Scholar
• Lovelace ES, Gunasekera S, Alvarmo C, Clark RJ, Nevin ST, Grishin AA, Adams DJ, Craik DJ, Daly NL. 2011. Stabilization of α-conotoxin AuIB: influences of disulfide connectivity and backbone cyclization. Antioxid Redox Signal. 14(1):87–95.
   PubMed Web of Science ®Google Scholar
• Lutolf M, Hubbell J. 2005. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol. 23(1):47–55.
   PubMed Web of Science ®Google Scholar
• MacKenzie AR, Marchington AP, Middleton DS, Newman SD, Jones BC. 2002. Structure − activity relationships of 1-Alkyl-5-(3, 4-dichlorophenyl)-5-{2-[(3-substituted)-1-azetidinyl] ethyl}-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor. J Med Chem. 45(24):5365–5377.
   PubMed Web of Science ®Google Scholar
• Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H. 2009. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem. 52(24):7993–8001.
   PubMed Web of Science ®Google Scholar
• Manna JD, Richardson SJ, Moghaddam MF. 2017. Implementation of a novel ultra fast metabolic stability analysis method using exact mass TOF-MS. Bioanalysis. 9(4):359–368.
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Bredberg U, Andersson TB. 2003. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet. 42(6):515–528.
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. 2004. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos. 32(11):1247–1253.
   PubMed Web of Science ®Google Scholar
• Meech R, Mackenzie PI. 1997. Structure and function of uridine diphosphate glucuronosyltransferases. Clin Exp Pharmacol Physiol. 24(12):907–915.
   PubMed Web of Science ®Google Scholar
• Miwa GT, Lu AY. 1987. Kinetic isotope effects and 'metabolic switching' in cytochrome P450-catalyzed reactions. Bioessays. 7(5):215–219.
   PubMed Web of Science ®Google Scholar
• Miyauchi S, Sawada Y, Iga T, Hanano M, Sugiyama Y. 1993. Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm Res. 10(3):434–440.
   PubMed Web of Science ®Google Scholar
• Morales A, Gallegos R, Uttamsingh V, Cheng C, Harbeson S, Zelle R, Tung R, Wells D. 2008. Increased in vitro metabolic stability and in vivo exposure in rats of precision-deuterated indiplon, Abstract 285. The 15th North American Meeting of the International Society of Xenobiotics; October 12-16; San Diego, CA.
   Google Scholar
• Muttenthaler M, King GF, Adams DJ, Alewood PF. 2021. Trends in peptide drug discovery. Nat Rev Drug Discov. 20(4):309–325.
   PubMed Web of Science ®Google Scholar
• Nägele E, Fandino AS. 2007. Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast liquid chromatography time-of-flight mass spectrometry. J Chromatogr A. 1156(1-2):196–200.
   PubMed Web of Science ®Google Scholar
• Nelson SD, Trager WF. 2003. The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos. 31(12):1481–1497.
   PubMed Web of Science ®Google Scholar
• Nielsen TE, Le Quement S, Meldal M. 2005. Solid-phase synthesis of bicyclic dipeptide mimetics by intramolecular cyclization of alcohols, thiols, amines, and amides with N-acyliminium intermediates. Org Lett. 7(17):3601–3604.
   PubMed Web of Science ®Google Scholar
• Norona LM, Nguyen DG, Gerber DA, Presnell SC, LeCluyse EL. 2016. Editor’s highlight: modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues. Toxicol Sci. 154(2):354–367.
   PubMed Web of Science ®Google Scholar
• O'Connor D, Mortishire‐Smith R, Morrison D, Davies A, Dominguez M. 2006. Ultra-performance liquid chromatography coupled to time-of-flight mass spectrometry for robust, high-throughput quantitative analysis of an automated metabolic stability assay, with simultaneous determination of metabolic data. Rapid Commun Mass Spectrom. 20(5):851–857.
   PubMed Web of Science ®Google Scholar
• Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 27(11):1350–1359.
   PubMed Web of Science ®Google Scholar
• Oppermann FS, Klammer M, Bobe C, Cox J, Schaab C, Tebbe A, Daub H. 2013. Comparison of SILAC and mTRAQ quantification for phosphoproteomics on a quadrupole orbitrap mass spectrometer. J Proteome Res. 12(9):4089–4100.
   PubMed Web of Science ®Google Scholar
• Palani A, Shapiro S, Josien H, Bara T, Clader JW, Greenlee WJ, Cox K, Strizki JM, Baroudy BM. 2002. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem. 45(14):3143–3160.
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. 1977. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 5(6):625–653.
   PubMedGoogle Scholar
• Papeleu P, Vanhaecke T, Henkens T, Elaut G, Vinken M, Snykers S, Rogiers V. 2006. Isolation of rat hepatocytes. Cytochrome P450 Protocols. Humana; p. 229–237.
   Google Scholar
• Parcella K, Eastman K, Yeung K-S, Grant-Young KA, Zhu J, Wang T, Zhang Z, Yin Z, Parker D, Mosure K, et al. 2017. Improving metabolic stability with deuterium: the discovery of BMT-052, a pan-genotypic HCV NS5B polymerase inhibitor. ACS Med Chem Lett. 8(7):771–774.
   PubMed Web of Science ®Google Scholar
• Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, et al. 1996. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys. 331(2):145–169.
   PubMed Web of Science ®Google Scholar
• Pirali T, Serafini M, Cargnin S, Genazzani AA. 2019. Applications of deuterium in medicinal chemistry. J Med Chem. 62(11):5276–5297.
   PubMed Web of Science ®Google Scholar
• Projean D, Baune B, Farinotti R, Flinois J-P, Beaune P, Taburet A-M, Ducharme J. 2003. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 31(6):748–754.
   PubMed Web of Science ®Google Scholar
• Qian K, Yu D, Chen C-H, Huang L, Morris-Natschke SL, Nitz TJ, Salzwedel K, Reddick M, Allaway GP, Lee K-H. 2009. Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents. J Med Chem. 52(10):3248–3258.
   PubMed Web of Science ®Google Scholar
• Ranasinghe A, Ramanathan R, Jemal M, D’Arienzo CJ, Humphreys WG, Olah TV. 2012. Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. Bioanalysis. 4(5):511–528.
   PubMed Web of Science ®Google Scholar
• Rane A, Wilkinson G, Shand D. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther. 200(2):420–424.
   PubMed Web of Science ®Google Scholar
• Reissmann S, Imhof D. 2004. Development of conformationally restricted analogues of bradykinin and somatostatin using constrained amino acids and different types of cyclization. Curr Med Chem. 11(21):2823–2844.
   PubMed Web of Science ®Google Scholar
• Robert MS, Rowland M. 1985. Hepatic eliminatilon—dispersion model. J Pharm Sci. 74(5):585–587.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. 1999. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol. 57(5):465–480.
   PubMed Web of Science ®Google Scholar
• Ross KL, Tu TT, Smith S, Dalluge JJ. 2007. Profiling of organic acids during fermentation by ultraperformance liquid chromatography-tandem mass spectrometry. Anal Chem. 79(13):4840–4844.
   PubMed Web of Science ®Google Scholar
• Rowland M, Benet LZ, Graham GG. 1973. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1(2):123–136.
   PubMedGoogle Scholar
• Saliem M, Holm F, Tengzelius RB, Jorns C, Nilsson L-M, Ericzon B-G, Ellis E, Hovatta O. 2012. Improved cryopreservation of human hepatocytes using a new xeno free cryoprotectant solution. WJH. 4(5):176–183.
   PubMedGoogle Scholar
• Schneider F, Bradbury M, Baillie TA, Stamler D, Hellriegel E, Cox DS, Loupe PS, Savola JM, Rabinovich‐Guilatt L. 2020. Pharmacokinetic and metabolic profile of deutetrabenazine (TEV-50717) compared with tetrabenazine in healthy volunteers. Clin Transl Sci. 13(4):707–717.
   PubMed Web of Science ®Google Scholar
• Schneider G. 2018. Automating drug discovery. Nat Rev Drug Discov. 17(2):97–113.
   PubMed Web of Science ®Google Scholar
• Schneider G, Coassolo P, Lavé T. 1999. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. J Med Chem. 42(25):5072–5076.
   PubMed Web of Science ®Google Scholar
• Schneider F, Hillgenberg M, Koytchev R, Alken R-G. 2006. Enhanced plasma concentration by selective deuteration of rofecoxib in rats. Arzneimittelforschung. 56(4):295–300.
   PubMed Web of Science ®Google Scholar
• Sharma R, Strelevitz TJ, Gao H, Clark AJ, Schildknegt K, Obach RS, Ripp SL, Spracklin DK, Tremaine LM, Vaz AD. 2012. Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos. 40(3):625–634.
   PubMed Web of Science ®Google Scholar
• Shou WZ. 2020. Current status and future directions of high-throughput ADME screening in drug discovery. J Pharm Anal. 10(3):201–208.
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Liu F, Omiecinski CJ. 2004. Phenobarbital responsiveness as a uniquely sensitive indicator of hepatocyte differentiation status: requirement of dexamethasone and extracellular matrix in establishing the functional integrity of cultured primary rat hepatocytes. Exp Cell Res. 292(2):252–264.
   PubMed Web of Science ®Google Scholar
• Simpson GL, Bertrand SM, Borthwick JA, Campobasso N, Chabanet J, Chen S, Coggins J, Cottom J, Christensen SB, Dawson HC, et al. 2019. Identification and optimization of novel small c-Abl kinase activators using fragment and HTS methodologies. J Med Chem. 62(4):2154–2171.
   PubMed Web of Science ®Google Scholar
• Sliwoski G, Kothiwale S, Meiler J, Lowe EW. 2014. Computational methods in drug discovery. Pharmacol Rev. 66(1):334–395.
   PubMed Web of Science ®Google Scholar
• Stringer RA, Williams G, Picard F, Sohal B, Kretz O, McKenna J, Krauser JA. 2014. Application of a deuterium replacement strategy to modulate the pharmacokinetics of 7-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-3-(4-methoxy-2-methylphenyl)-2,6-dimethylpyrazolo[5,1-b]oxazole, a novel CRF1 antagonist. Drug Metab Dispos. 42(5):954–962.
   PubMed Web of Science ®Google Scholar
• Stürzebecher S, Haberey M, Müller B, Schillinger E, Schröder G, Skuballa W, Stock G, Vorbrüggen H, Witt W. 1986. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins. 31(1):95–109.
   PubMed Web of Science ®Google Scholar
• Tagat JR, Steensma RW, McCombie SW, Nazareno DV, Lin S-I, Neustadt BR, Cox K, Xu S, Wojcik L, Murray MG. 2001. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2, 4-Dimethyl-3-pyridinyl) carbonyl]-4-methyl-4-[3 (S)-methyl-4-[1 (S)-[4-(trifluoro-methyl) phenyl] ethyl]-1-piperazinyl]-piperidine N 1-Oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem. 44(21):3343–3346.
   PubMed Web of Science ®Google Scholar
• Tasnim F, Toh Y-C, Qu Y, Li H, Phan D, Narmada BC, Ananthanarayanan A, Mittal N, Meng RQ, Yu H. 2016. Functionally enhanced human stem cell derived hepatocytes in galactosylated cellulosic sponges for hepatotoxicity testing. Mol Pharm. 13(6):1947–1957.
   PubMed Web of Science ®Google Scholar
• Thompson TN. 2000. Early ADME in support of drug discovery: the role of metabolic stability studies. Curr Drug Metab. 1(3):215–241.
   PubMed Web of Science ®Google Scholar
• Tucker G. 1981. Measurement of the renal clearance of drugs. Br J Clin Pharmacol. 12(6):761–770.
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. 2001. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther. 70(2):103–114.
   PubMedGoogle Scholar
• Tung R. 2010. The development of deuterium-containing drugs. Innov Pharm Technol. 32(32):24–28.
   Google Scholar
• Turncliff RZ, Meier PJ, Brouwer KL. 2004. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab Dispos. 32(8):834–839.
   PubMed Web of Science ®Google Scholar
• van Dam JC, Eman MR, Frank J, Lange HC, van Dedem GW, Heijnen SJ. 2002. Analysis of glycolytic intermediates in Saccharomyces cerevisiae using anion exchange chromatography and electrospray ionization with tandem mass spectrometric detection. Anal Chim Acta. 460(2):209–218.
   Web of Science ®Google Scholar
• Vorrink SU, Ullah S, Schmidt S, Nandania J, Velagapudi V, Beck O, Ingelman‐Sundberg M, Lauschke VM. 2017. Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics . Faseb J. 31(6):2696–2708.
   PubMed Web of Science ®Google Scholar
• Wenthur CJ, Morrison R, Felts AS, Smith KA, Engers JL, Byers FW, Daniels JS, Emmitte KA, Conn PJ, Lindsley CW. 2013. Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM). J Med Chem. 56(12):5208–5212.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. 1975. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 18(4):377–390.
   PubMed Web of Science ®Google Scholar
• Williamson LN, Bartlett MG. 2007. Quantitative liquid chromatography/time-of-flight mass spectrometry. Biomed Chromatogr. 21(6):567–576.
   PubMed Web of Science ®Google Scholar
• Wu X, Huang Y-H, Kaas Q, Harvey PJ, Wang CK, Tae H-S, Adams DJ, Craik DJ. 2017. Backbone cyclization of analgesic conotoxin GeXIVA facilitates direct folding of the ribbon isomer. J Biol Chem. 292(41):17101–17112.
   PubMed Web of Science ®Google Scholar
• Xu R, Manuel M, Cramlett J, Kassel DB. 2010. A high throughput metabolic stability screening workflow with automated assessment of data quality in pharmaceutical industry. J Chromatogr A. 1217(10):1616–1625.
   PubMed Web of Science ®Google Scholar
• Yamada S, Otto PS, Kennedy DL, Whayne TF. 1980. The effects of dexamethasone on metabolic activity of hepatocytes in primary monolayer culture. In Vitro. 16(7):559–570.
   PubMedGoogle Scholar
• Yang J, Zhang G, Wang Z, Meng J, Wen H. 2021. Metabolic study of stable isotope labeled indolinone derivative in hepatocyte cell by UPLC/Q TOF MS. J Am Soc Mass Spectrom. 32(6):1538–1544.
   PubMed Web of Science ®Google Scholar
• Yin Y, Han G, Zhou J, Dillon M, McCarty L, Gavino L, Ellerman D, Spiess C, Sandoval W, Carter PJ. 2016. Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry. MAbs. 8(8):1467–1476.
   PubMed Web of Science ®Google Scholar
• Zhang D, Luo G, Ding X, Lu C. 2012. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B. 2(6):549–561.
   Google Scholar
• Zhang H, Liu C, Hua W, Ghislain LP, Liu J, Aschenbrenner L, Noell S, Dirico K, Lanyon LF, Steppan CM. 2021. Acoustic ejection mass spectrometry for high-throughput analysis. Anal Chem. 93(31):10850-10861.
   Google Scholar
• Zhang J, Vath M, Ferraro C, Li Y, Murphy K, Zvyaga T, Weller H, Shou W. 2013. A high-speed liquid chromatography/tandem mass spectrometry platform using multiplexed multiple-injection chromatography controlled by single software and its application in discovery ADME screening. Rapid Commun Mass Spectrom. 27(7):731–737.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhang H, Humphreys WG. 2011. Drug metabolite profiling and identification by high-resolution mass spectrometry. J Biol Chem. 286(29):25419–25425.
   PubMed Web of Science ®Google Scholar
• Żołnowska B, Sławiński J, Belka M, Bączek T, Kawiak A, Chojnacki J, Pogorzelska A, Szafrański K. 2015. Synthesis, molecular structure, metabolic stability and QSAR studies of a novel series of anticancer N-acylbenzenesulfonamides. Molecules. 20(10):19101–19129.
   PubMed Web of Science ®Google Scholar